Published in N Engl J Med on July 05, 1979
Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med (2005) 4.92
Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg (1992) 4.50
Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A (2005) 2.73
Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum (2008) 2.62
Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med (2006) 2.53
Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat Rev Genet (2009) 2.46
Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol (2013) 2.36
Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c⁺ B-cell population is important for the development of autoimmunity. Blood (2011) 2.20
Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev (2008) 2.13
A genomic approach to human autoimmune diseases. Annu Rev Immunol (2010) 2.10
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum (2012) 2.03
Molecular cloning of human immune interferon cDNA and its expression in eukaryotic cells. Nucleic Acids Res (1982) 2.01
Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest (2004) 1.82
Aicardi-Goutières syndrome and the type I interferonopathies. Nat Rev Immunol (2015) 1.82
Interferon regulatory factors in human lupus pathogenesis. Transl Res (2011) 1.81
Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum (2007) 1.80
Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum (2011) 1.79
Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol (1987) 1.76
Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol (2010) 1.73
Interferon alpha as a primary pathogenic factor in human lupus. J Interferon Cytokine Res (2011) 1.69
Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol (2007) 1.69
Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum (2010) 1.67
Microarray analysis of gene expression in lupus. Arthritis Res Ther (2003) 1.67
Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol (2009) 1.64
The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. Arthritis Rheum (2008) 1.59
Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus. Genes Immun (2009) 1.58
Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol (2008) 1.58
Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis (2005) 1.57
IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J Clin Invest (2008) 1.55
Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol (2009) 1.55
Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J Clin Invest (2004) 1.52
A novel type I IFN-producing cell subset in murine lupus. J Immunol (2008) 1.50
Genetic regulation of serum cytokines in systemic lupus erythematosus. Transl Res (2009) 1.49
Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus (2009) 1.47
Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res Ther (2010) 1.45
Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop. J Immunol (2009) 1.42
Human B lymphoma cell line producing B cell growth factor. J Clin Invest (1985) 1.41
IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis (2011) 1.38
Siglec-H protects from virus-triggered severe systemic autoimmunity. J Exp Med (2016) 1.37
Interferon messenger RNA is produced constitutively in the organs of normal individuals. Proc Natl Acad Sci U S A (1987) 1.36
Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum (2009) 1.36
New roles for the major human 3'-5' exonuclease TREX1 in human disease. Cell Cycle (2008) 1.35
Recent advances in the genetics of systemic lupus erythematosus. Expert Rev Clin Immunol (2010) 1.35
The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression. EMBO J (2005) 1.34
Detection of gamma interferon in the sera of patients with Behçet's disease. Infect Immun (1982) 1.33
Interferon production of vitro by leucocytes from patients with systemic lupus erythematosus and rheumatoid arthritis. Clin Exp Immunol (1981) 1.32
Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther (2010) 1.32
A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. EMBO Mol Med (2011) 1.29
Type I interferon in the pathogenesis of lupus. J Immunol (2014) 1.29
Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus. Arthritis Rheum (2010) 1.27
The search for lupus biomarkers. Best Pract Res Clin Rheumatol (2009) 1.26
SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature. PLoS One (2013) 1.25
Preferential activation of helper/inducer T lymphocytes in autoimmune chronic active hepatitis. Clin Exp Immunol (1987) 1.23
The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol (2011) 1.22
Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus. Hum Genomics Proteomics (2009) 1.22
Lymphocyte abnormalities in Behçet's syndrome. Clin Exp Immunol (1980) 1.20
Interferon alpha-induced lupus: proof of principle. J Clin Rheumatol (2008) 1.20
Severity of lymphocytic choriomeningitis virus disease in different strains of suckling mice correlates with increasing amounts of endogenous interferon. J Exp Med (1980) 1.19
Immune interferon in serum and synovial fluid in rheumatoid arthritis and related disorders. Ann Rheum Dis (1983) 1.19
Interferon-induced 2'-5' adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon. J Exp Med (1983) 1.18
Type I interferon and systemic lupus erythematosus. J Interferon Cytokine Res (2011) 1.18
Enhanced MHC class II expression in renal proximal tubules precedes loss of renal function in MRL/lpr mice with lupus nephritis. Am J Pathol (1989) 1.17
Advances in understanding the pathogenesis of primary Sjögren's syndrome. Nat Rev Rheumatol (2013) 1.16
How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets. Immunol Rev (2008) 1.15
The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res (2011) 1.14
Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro. Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis. Clin Exp Immunol (1982) 1.14
The type I interferon signaling pathway is a target for glucocorticoid inhibition. Mol Cell Biol (2010) 1.14
IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci U S A (2009) 1.11
Dissecting the immune cell mayhem that drives lupus pathogenesis. Sci Transl Med (2011) 1.11
Direct Toll-like receptor 2 mediated co-stimulation of T cells in the mouse system as a basis for chronic inflammatory joint disease. Arthritis Res Ther (2004) 1.11
Natural killer cells are present in the normal human lung but are functionally impotent. J Clin Invest (1984) 1.11
The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci (2011) 1.10
Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A (2012) 1.10
Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha. Clin Immunol (2012) 1.09
Interferon-alpha: a therapeutic target in systemic lupus erythematosus. Rheum Dis Clin North Am (2010) 1.08
Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther (2006) 1.06
Promoter variant of PIK3C3 is associated with autoimmunity against Ro and Sm epitopes in African-American lupus patients. J Biomed Biotechnol (2010) 1.05
Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus (2012) 1.05
Cytokines in systemic lupus erythematosus. Curr Mol Med (2009) 1.03
Disturbance of cytokine networks in Sjögren's syndrome. Arthritis Res Ther (2011) 1.02
IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice. J Immunol (2012) 1.02
Interferon-gamma production by peripheral blood mononuclear cells from patients with Behçet's syndrome. Clin Exp Immunol (1984) 1.01
A candidate gene study of the type I interferon pathway implicates IKBKE and IL8 as risk loci for SLE. Eur J Hum Genet (2010) 1.01
Rapid, quantitative, semiautomated assay for virus-induced and immune human interferons. J Clin Microbiol (1980) 1.01
Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. J Immunol (2013) 1.01
Gene-gene-sex interaction in cytokine gene polymorphisms revealed by serum interferon alpha phenotype in juvenile dermatomyositis. J Pediatr (2010) 1.00
Interferon regulatory factor 5 activation in monocytes of systemic lupus erythematosus patients is triggered by circulating autoantigens independent of type I interferons. Arthritis Rheum (2012) 1.00
Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus. Arthritis Res Ther (2010) 0.99
Potential role of IFNα in adult lupus. Arthritis Res Ther (2010) 0.98
Human fibroblast interferon in tears of patients with picornavirus epidemic conjunctivitis. Infect Immun (1980) 0.97
Interferon as a cause of endoplasmic reticulum abnormalities within hepatocytes in newborn mice. Br J Exp Pathol (1982) 0.96
A sensitive radioimmunoassay for alpha-interferon: circulating alpha-interferon-like substance in the plasma of healthy individuals and rheumatoid arthritis patients. Clin Exp Immunol (1986) 0.96
Neutrophil Extracellular Traps and Systemic Lupus Erythematosus. J Clin Cell Immunol (2013) 0.95
Innate pathways to B-cell activation and tolerance. Ann N Y Acad Sci (2010) 0.95
Interferon and natural killer cells in systemic lupus erythematosus. Clin Exp Immunol (1982) 0.95
Type 1 interferons and myositis. Arthritis Res Ther (2010) 0.95
Directing autoimmunity to nucleoprotein particles: the impact of dendritic cells and interferon alpha in lupus. J Exp Med (2003) 0.94
Nucleic acid sensing Toll-like receptors in autoimmunity. Curr Opin Immunol (2010) 0.94
Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases. J Immunol Res (2015) 0.93
Interferon system in patients with systemic juvenile chronic arthritis: in vivo and in vitro studies. Clin Exp Immunol (1983) 0.93
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis (2002) 20.48
Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum (1977) 8.55
Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum (1993) 7.14
Measurement of serum DNA-binding activity in systemic lupus erythematosus. N Engl J Med (1969) 6.16
Increased risk of lymphoma in sicca syndrome. Ann Intern Med (1978) 4.63
Effect of virus infections on the function of the immune system. Annu Rev Microbiol (1970) 4.30
Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. J Immunol (1983) 4.25
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med (1986) 4.01
Rheumatoid arthritis in Greek and British patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum (1992) 3.92
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis (1996) 3.68
Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature (1985) 3.62
Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med (1979) 3.62
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum (2005) 3.25
Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum (1999) 2.99
CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol Today (1989) 2.96
Thymus dependence of viral antigens. Nature (1975) 2.95
Heterogeneity in the properties of 7 S and 19S rabbit-neutralizing antibodies to herpes simplex virus. J Immunol (1968) 2.90
Continued expression of a poly(A)+ transcript of herpes simplex virus type 1 in trigeminal ganglia of latently infected mice. J Virol (1987) 2.78
Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science (1987) 2.75
Latent ganglionic infection with herpes simplex virus types 1 and 2: viral reactivation in vivo after neurectomy. Science (1974) 2.71
How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum (1985) 2.68
Infectious virus-antibody complex in the blood of chronically infected mice. J Exp Med (1966) 2.68
Probing the human B-cell repertoire with EBV: polyreactive antibodies and CD5+ B lymphocytes. Annu Rev Immunol (1989) 2.63
The foamy viruses. Bacteriol Rev (1975) 2.53
Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci U S A (1992) 2.48
Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV-1 infection: inhibition of mRNA expression. Nat Med (1997) 2.47
Molecular cloning and expression of RPE65, a novel retinal pigment epithelium-specific microsomal protein that is post-transcriptionally regulated in vitro. J Biol Chem (1993) 2.46
Inhibition or enhancement of immunological injury of virus-infected cells. Proc Natl Acad Sci U S A (1971) 2.45
Prevention of cell-to-cell spread of herpes simplex virus by leukocytes. J Exp Med (1973) 2.42
Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med (1983) 2.38
Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science (1985) 2.34
In vitro stimulation of sensitized lymphocytes by herpes simplex virus and vaccinia virus. Proc Natl Acad Sci U S A (1972) 2.29
Comparison of direct and indirect solid-phase microradioimmunoassays for the detection of viral antigens and antiviral antibody. Appl Microbiol (1973) 2.23
Immune mechanisms by which the spread of viral infections is stopped. Cell Immunol (1974) 2.23
Juvenile rheumatoid arthritis presenting in the adult as fever of unknown origin. Medicine (Baltimore) (1973) 2.21
HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology (1991) 2.16
Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. DNA Cell Biol (1994) 2.13
B-lymphocyte alloantigens associated with systemic lupus erythematosus. N Engl J Med (1978) 2.11
Virus-induced diabetes mellitus. XVIII. Inhibition by a nondiabetogenic variant of encephalomyocarditis virus. J Exp Med (1980) 2.07
Demonstration of activation of B lymphocytes in New Zealand black mice at birth by an immunoradiometric assay for murine IgM. J Immunol (1977) 2.06
The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome. Ann Rheum Dis (1994) 2.03
Herpes simplex virus DNA and mRNA sequences in acutely and chronically infected trigeminal ganglia of mice. Virology (1978) 1.99
IA-1, a new marker for neuroendocrine differentiation in human lung cancer cell lines. Cancer Res (1993) 1.96
Latent infection of sensory ganglia with herpes simplex virus: efficacy of immunization. Science (1975) 1.95
Immunological response restricts number of cells in sensory ganglia infected with herpes simplex virus. Nature (1976) 1.95
Herpes simplex virus DNA sequences in the CNS of latently infected mice. Nature (1980) 1.95
Molecular mimicry: frequency of reactivity of monoclonal antiviral antibodies with normal tissues. J Virol (1986) 1.95
Genetic differences between primary and secondary sicca syndrome. N Engl J Med (1979) 1.93
Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care (2000) 1.91
Incidence of infection in systemic lupus erythematosus. Arthritis Rheum (1974) 1.89
Nucleotide sequences of eight human natural autoantibody VH regions reveals apparent restricted use of VH families. J Immunol (1989) 1.88
Neutralization of an infectious herpes simplex virus-antibody complex by anti-gamma-globulin. Proc Natl Acad Sci U S A (1966) 1.84
Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J Virol (1988) 1.81
Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med (1979) 1.79
Rapid micro-radioimmunoassay for the measurement of antiviral antibody. J Immunol (1972) 1.79
Virus-induced autoimmunity: monoclonal antibodies that react with endocrine tissues. Science (1983) 1.78
Latent infection of the peripheral ANS with herpes simplex virus. Nature (1975) 1.76
Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum (2000) 1.74
Human monoclonal autoantibodies that react with multiple endocrine organs. N Engl J Med (1983) 1.73
Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum (1982) 1.73
Enhancement of IgE-mediated histamine release from human basophils by viruses: role of interferon. J Exp Med (1977) 1.73
Virus-induced diabetes mellitus. XX. Polyendocrinopathy and autoimmunity. J Exp Med (1981) 1.72
Elevated gamma-globulin and increased antibody production in mice infected with lactic dehydrogenase virus. J Exp Med (1966) 1.71
IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A (1996) 1.71
Acute and latent infection of sensory ganglia with herpes simplex virus: immune control and virus reactivation. J Gen Virol (1979) 1.71
Cyclophosphamide in lupus nephritis: a controlled trial. Ann Intern Med (1971) 1.70
Lymphocytes capable of making monoclonal autoantibodies that react with multiple organs are a common feature of the normal B cell repertoire. J Immunol (1984) 1.69
Virus-induced diabetes mellitus. I. Hyperglycemia and hypoinsulinemia in mice infected with encephalomyocarditis virus. J Exp Med (1973) 1.68
Homology between murine and human cellular DNA sequences and the terminal repetition of the S component of herpes simplex virus type 1 DNA. Cell (1982) 1.67
Clonal analysis of a human antibody response. II. Sequences of the VH genes of human IgM, IgG, and IgA to rabies virus reveal preferential utilization of VHIII segments and somatic hypermutation. J Immunol (1993) 1.65
Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol (1993) 1.64
Multiple organ-reactive monoclonal autoantibodies. Nature (1983) 1.64
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64
Neutralization of sensitized virus by purified components of complement. Proc Natl Acad Sci U S A (1970) 1.63
Monoreactive high affinity and polyreactive low affinity rheumatoid factors are produced by CD5+ B cells from patients with rheumatoid arthritis. J Exp Med (1988) 1.62
Hypokalaemic paralysis as the presenting manifestation of primary Sjögren's syndrome. Nephrol Dial Transplant (1994) 1.62
Bladder toxicity with chronic oral cyclophosphamide therapy in nonmalignant disease. Arthritis Rheum (1973) 1.61
NIH conference. Rheumatoid arthritis: evolving concepts of pathogenesis and treatment. Ann Intern Med (1984) 1.61
Prevention of ultraviolet-light-induced herpes labialis by sunscreen. Lancet (1991) 1.60
Primary amyloidosis. Clinical, immunochemical and immunoglobulin metabolism. Studies in fifteen patients. Am J Med (1969) 1.60
NIH conference. Systemic lupus erythematosus: evolving concepts. Ann Intern Med (1979) 1.59
Mechanisms of interferon-induced inhibition of Toxoplasma gondii replication in human retinal pigment epithelial cells. Infect Immun (1996) 1.59
High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol (1987) 1.59
Cytotoxic autoantibodies to beta cells in the serum of patients with insulin-dependent diabetes mellitus. N Engl J Med (1980) 1.59
Capillary tube migration for detection of human delayed hypersensitivity: difficulties encountered with "buffy coat" cells and tuberculin antigen. J Immunol (1969) 1.57
Anti-Ro(SSA) positive rheumatoid arthritis (RA): a clinicoserological group of patients with high incidence of D-penicillamine side effects. Ann Rheum Dis (1985) 1.56
Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis (2006) 1.54
Lymphoma development in Sjögren's syndrome: novel p53 mutations. Arthritis Rheum (1999) 1.53
Cellular immunity to herpes simplex virus mediated by interferon. J Exp Med (1974) 1.52
Virus-induced diabetes mellitus. XV. Beta cell damage and insulin-dependent hyperglycemia in mice infected with coxsackie virus B4. J Exp Med (1978) 1.52
Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Proc Natl Acad Sci U S A (1996) 1.51
Sjögren's syndrome in patients with the CREST variant of progressive systemic scleroderma. J Rheumatol (1991) 1.51
Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int (2000) 1.50